Last updated on November 2017

Research Study for Chronic Obstructive Pulmonary Disease (COPD)


Brief description of study

Research Study for Chronic Obstructive Pulmonary Disease (COPD)

Detailed Study Description

This is a research study for chronic obstructive pulmonary disease (COPD). Subjects who meet inclusion criteria will be assigned to one of three doses of tiotropium. Two of these doses will be delivered via a novel inhalation device. The third dose will be delivered by the HandiHaler.

This study is for male and female patients age 40 or older who meet spirometry criteria. Patients may not have any other significant respiratory diseases. Oxygen will be allowed if used less than 12 hours per day.

This study is expected to last 2 to 3 ½ years and consist of approximately 10-17 treatment visits. This may change depending on the number of events reported to the pharmaceutical company. At the screening visit, subjects will have a physical examination, EKG and may perform pulmonary function testing at no charge. Subsequent visits will consist of assessment of health and possibly pulmonary function testing. Visit intervals will be from 6 to 12 weeks with interim telephone contacts to assess health and well being.

All study related medication and assessments will be at no charge to the participant. Subjects will be reimbursed for their time and travel.

Clinical Study Identifier: TX1506

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jessica Elkins Hochstetler RN, CCRC

Emerald Coast Research Associates
Panama City, FL USA
  Connect »

Jessica Elkins Hochstetler RN, CCRC

Emerald Coast Research Associates
Panama City, FL USA
  Connect »